2 completed, 1 active not recruiting, 1 terminated. 4 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 2, Active not recruiting 1, Terminated 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Chronic: new trials by email Literature Review of Chronic trials Research Report on Chronic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia rhIL-15, Obinutuzumab - Leukemia, Lymphocytic | Phase 1 | Terminated | National Cancer Institute (NCI) | 1 | 2019-07-11 | 2022-03-22 |
| Wound Healing Endpoint and Recurrence Epiceram Skin Barrier Function, Vaseline Petroleum Jelly - Chronic Wound, Burn Wound | Phase 1 / Phase 2 | Active not recruiting | Sashwati Roy | 100 | 2019-01-08 | 2025-09-26 |
| Functional Magnetic Resonance Imaging (fMRI) and Robot-Assisted Practice of Activities of Daily Living Robot Therapy Device, Occupational Therapy - Hemiparesis, Ischemic Stroke | Phase 1 | Completed | Medical College of Wisconsin | 61 | 2008-11-01 | 2014-02-04 |
| Use of Busulfan as Conditioning Agent for a Second Stem Cell Transplant Busulfan - Granulomatous Disease, Chronic | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 2 | 2004-09-23 | 2017-07-02 |
Bronchiolitis Obliterans Syndrome (4) · Burns (1) · Diabetic Foot (1) · Granulomatous Disease, Chronic (1) · Ischemic Stroke (1) · Leukemia (1) · Paresis (1) · Pressure Ulcer (1) · Stroke (1) · Wounds and Injuries (1)
Bronchial Diseases (4) · Bronchiolitis (4) · Bronchiolitis Obliterans (4) · Bronchitis (4) · Graft vs Host Disease (4) · Immune System Diseases (4) · Lung Diseases (4) · Lung Diseases, Obstructive (4) · Organizing Pneumonia (4) · Respiratory Tract Diseases (4) · Cardiovascular Diseases (2) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Pathological Conditions, Signs and Symptoms (2) · Vascular Diseases (2)
Busulfan (1) · Interleukin-15 (1) · Occupational Therapy (1) · Petroleum (1) · obinutuzumab (1)
Medical College of Wisconsin (1) · National Cancer Institute (NCI) (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Sashwati Roy (1)
United States (4)
Kevin C Conlon, M.D. (1) · Michel Torbey, MD (1) · Sashwati Roy, PhD (1)